Adia Med Expands Into Wound Care, Targeting High-Demand $25 Billion Market and Unlocking New Growth Avenues
Rhea-AI Summary
Adia Nutrition Inc. (OTCQB: ADIA) has announced its clinical division, Adia Med's expansion into the advanced wound care market, valued at $25.84 billion in 2025. The market is projected to reach $38.39 billion by 2034, driven by growing demand from 8.2 million Americans requiring chronic wound treatment annually.
The company will initially offer wound care services at its Winter Park, Florida clinic, with plans for expansion. Adia Med is already in-network with major insurers including UnitedHealthcare and Aetna, facilitating immediate patient access. The expansion targets high-reimbursement opportunities while addressing critical healthcare needs, particularly for diabetic foot ulcers, pressure sores, and post-surgical wounds.
Positive
- Entry into large $25.84 billion wound care market with projected growth to $38.39 billion by 2034
- Existing insurance partnerships with major providers UnitedHealthcare and Aetna
- High-reimbursement category with strong insurance support
- Large addressable market of 8.2 million Americans requiring wound care annually
Negative
- Initial operations limited to single Winter Park, Florida clinic
- Entering competitive market with established players
- Success dependent on patient volume and insurance approvals
News Market Reaction – ADIA
On the day this news was published, ADIA declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Winter Park, Florida--(Newsfile Corp. - August 20, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded company at the forefront of regenerative medicine and personalized health solutions, today announced that its clinical division, Adia Med, is officially expanding into the high-demand field of advanced wound care. This strategic move enables the company to serve a wider patient base, meet a critical and growing healthcare need, and open a new stream of revenue that supports long-term shareholder value.
Every year, an estimated 8.2 million Americans require medical treatment for chronic wounds, including diabetic foot ulcers, pressure sores, post-surgical wounds, and injuries resulting from poor circulation. These conditions are particularly prevalent among older adults and individuals with diabetes or vascular disease. Of those patients, approximately 1.6 million undergo skin graft procedures annually as part of their treatment and recovery process. As the population ages and chronic diseases become more widespread, the demand for advanced wound care is expected to rise sharply over the next decade.
The wound care market is valued at
By entering this sector, Adia Med is responding directly to market demand while establishing a scalable revenue stream that aligns with its broader clinical strategy. The company will begin offering wound care services at its flagship Winter Park, Florida clinic, with plans to expand based on patient volume, clinical partnerships, and insurance approval. Services will include personalized wound evaluations, evidence-based protocols, and regenerative support therapies designed to accelerate healing, reduce complications, and improve patient outcomes.
"This expansion into wound care is both a mission-driven and market-smart decision," said Larry Powalisz, CEO of Adia Nutrition Inc. "We're addressing a real and growing problem that impacts millions of people, while also adding a new layer of value for our shareholders. Wound care represents a stable, high-reimbursement category with strong insurance support and we're stepping in with the tools, talent, and strategy to do it right."
Adia Med is currently in-network with major insurance providers including UnitedHealthcare and Aetna, positioning the company to make wound care services accessible and affordable for a large number of patients from day one. This move also reinforces Adia Med's commitment to integrated, whole-person care by adding a new service line that complements its existing wellness and regenerative health offerings.
As the company continues to grow, wound care will serve as both a meaningful healthcare solution and a durable revenue vertical contributing to Adia Med's mission of expanding access, driving innovation, and delivering sustainable returns for investors.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262972
FAQ
What is the size of the wound care market that Adia Med (OTCQB: ADIA) is entering?
How many patients require wound care treatment in the US according to Adia Med?
Which insurance providers is Adia Med in-network with for wound care services?
Where will Adia Med initially offer its wound care services?
What types of wounds will Adia Med treat in its new wound care division?
